Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic Steatohepatitis

Nonalcoholic Steatohepatitis Clinical Trial

Official title:

A Randomized, Double-Blind, Placebo-Controlled Dosing, Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic Steatohepatitis

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01466894
• Other study ID #: NASH-Immuron-002
• Status: Withdrawn
• Phase: Phase 2
• First received: November 2, 2011
• Last updated: December 4, 2012
• Start date: December 2012
• Est. completion date: December 2013

Study information

• Verified date: December 2012
• Source: Immuron Ltd.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationIsrael: Ministry of HealthAustralia: Therapeutic Goods Administration
• Study type: Interventional

Clinical Trial Summary

This is a multi-center, randomized, placebo-controlled, double-blind, dose-selection, multiple dose administration study comprising three groups, with up to 40 patients in each active treatment and placebo group. Patients with biopsy proven nonalcoholic steatohepatitis (NASH) and elevated liver enzymes will be randomized to undergo a liver MRI scan and to receive Imm 124-E or placebo for 24 weeks. During this period, patients will be followed for clinical and laboratory effects. At the end of 24 weeks of treatment, patients will undergo a second liver MRI scan. Patients will be followed for an additional 4 weeks for safety after completion of treatment.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 2013
• Est. primary completion date: December 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Men and women age 18 to 75 years (inclusive)

• Subjects with biopsy proven NASH (NAS = 4) within one year prior to screening

• Elevated liver enzymes at screening and at least once within past 6 months (ALT > 30 women, ALT > 40 men)

• Normal or only slightly impaired synthetic liver function (serum albumin >3.5gm%, INR 0.8-1.5)

• BMI 18 to 40 (inclusive)

• Subjects able to adhere to the visit schedule and protocol requirements and be available to complete the study

• Women of child bearing potential must be using adequate contraception

Exclusion Criteria:

• Cow milk allergy or lactose intolerance

• Excessive alcohol use (Women > 20 grams/day, Men > 40 grams/day).

• Current treatment with Insulin or Incretins

• Decompensated liver disease

• Other or concomitant cause of liver disease (viral hepatitis, autoimmune liver disease, metabolic liver disease, vascular liver disease)

• Subjects who known to be HIV positive

• Subjects who have undergone surgery within the last 3 months

• Subjects who have had a prior gastrointestinal surgery

• Subjects who have a history of Inflammatory Bowel Disease

• Subjects who are receiving an elemental diet or parenteral nutrition

• Subjects with an infectious, immune-mediated or active malignant disease (during the last 3 months)

• Subjects with known clinically significant systemic disease

• Subjects treated with other anti-NASH therapy(s) - thiazolidinediones, vitamin E, SAM-e, betaine, milk thistle, gemfibrozil, anti-TNF therapies and probiotics) - within 3 months of the liver biopsy

• Subjects who have been treated with any type of immune modulatory drug, including systemic steroids or NSAIDs, within the last 3 months

• Subjects who have received either Immuron, 6-MP, Methotrexate, Cyclosporine, anti-TNF alpha therapies (Infliximab, Adalimumab, Etanercept) or anti-integrin therapies (namixilab) within the past 12 months

• Known history of drug or alcohol abuse, including positive urinary drugs of abuse screen at the screening visit

• Subjects who are pregnant as confirmed on screening test

• Any acute medical situation (e.g. acute infection) within 48 hours of study start that is considered of significance by the Principal Investigator

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Fatty Liver
• Nonalcoholic Steatohepatitis

Intervention

Biological:
• IMM 124-E
Tablets orally twice a day for 24 weeks
• Placebo
Tablets orally twice daily for 24 weeks

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Immuron Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety outcome	No unexpected treatment related SAEs throughout the participation period and the follow up period	28 weeks	Yes
Secondary	MRI liver fat quantitation	Improvement in MRI fat quantification as determined by a decrease in the fat content by 5% or more from baseline to week 24	Baseline and 24 weeks	No
Secondary	ALT levels	Normalization of alanine aminotransferase levels in patients with NASH from baseline to week 24	Baseline and 24 weeks	No
Secondary	Liver enzyme improvement	Improvement in liver enzymes by 20% from baseline from baseline to week 24	Baseline and 24 weeks	No
Secondary	Lipid profile	Improvement in lipid profile by 20% from baseline from baseline to week 24	Baseline and 24 weeks	No
Secondary	HbA1c	Improvement in HBA1c by 0.5 % from baseline from baseline to week 24	Baseline and 24 weeks	No